NeuroSense Therapeutics/$NRSN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
- Ticker
- $NRSN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 17
- Headquarters
- Herzliya, Israel
- Website
- www.neurosense-tx.com
NRSN Metrics
BasicAdvanced
$3.3M
-
-$8.73
1.58
-
Price and volume
Market cap
$3.3M
Beta
1.58
52-week high
$7.50
52-week low
$1.10
Average daily volume
40K
Financial strength
Current ratio
0.309
Quick ratio
0.079
Long term debt to equity
-0.046
Total debt to equity
-0.109
Profitability
EBITDA (TTM)
-11.069
Management effectiveness
Return on assets (TTM)
-247.30%
Return on equity (TTM)
-2,174.98%
Valuation
Price to book
-1.86
Price to tangible book (TTM)
-1.86
Price to free cash flow (TTM)
-0.295
Free cash flow yield (TTM)
-338.60%
Free cash flow per share (TTM)
-6.027
Growth
Earnings per share change (TTM)
-20.45%
3-year earnings per share growth (CAGR)
-21.77%
What the Analysts think about NRSN
Analyst ratings (Buy, Hold, Sell) for NeuroSense Therapeutics stock.
Analyst projections of the future price of NeuroSense Therapeutics stock.
NRSN Financial Performance
Revenues and expenses
NRSN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.